Pneumococcal vaccine - Millenium Biologix
Alternative Names: Streptococcus pneumoniae vaccine - Millenium BiologixLatest Information Update: 02 Oct 2021
At a glance
- Originator Millenium Biologix Corporation
- Class Pneumococcal vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pneumococcal infections
Most Recent Events
- 06 Dec 2004 Millenium Biologix has merged with Cytovax Biotechnologies to form Millenium Biologix Corporation
- 16 Jun 2003 This programme is still in active development
- 05 Nov 2001 Preclinical development for Pneumococcal infections in Canada (Unknown route)